FDA slaps a partial hold on Avidity's mAb-siRNA therapy, pausing enrollment in muscle weakness disease study
Avidity Biosciences will have to wait to enroll new patients in a Phase I/II study of its therapy for myotonic dystrophy type 1, or DM1, which weakens muscles and leads to respiratory and cardiac issues.
The FDA is docking new enrollment in the MARINA study as the company and one of its trial investigators look into a serious adverse event reported in a patient in the 4 mg/kg cohort, the biotech said Tuesday morning. Patients currently enrolled can continue on the study drug or placebo and roll over into the open-label extension.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.